GLPwatch
Papers (10378)
Page 97 of 173, ranked by citation count.
- Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight.
- Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system.
- Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty.
- Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.
- Physiologically based pharmacokinetic modelling of semaglutide in children and adolescents with healthy and obese body weights.
- Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
- Semaglutide and GLP-1 analogues as weight-loss agents.
- Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.
- Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.
- Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
- Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.
- Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
- Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
- Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.
- Lixisenatide: A New Option for Managing Type 2 Diabetes.
- Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
- Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
- Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
- Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
- Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-β/Smad3 Signaling Pathway.
- Mazdutide versus placebo in Chinese adults with type 2 diabetes.
- Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.
- GLP-1 receptor agonist effects on normal and neoplastic pancreata.
- A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient.
- Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.
- Exendin-4 protects murine pancreatic β-cells from free fatty acid-induced apoptosis through PI-3K signaling.
- GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
- Implications of immortal person-time when outcomes are nonfatal.
- A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report.
- Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion.
- Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.
- Is insulin the preferred treatment for HbA1c >9%?
- Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
- FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
- Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.
- Liraglutide treatment counteracts alterations in adipose tissue metabolism induced by orchiectomy in rats.
- The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes-A Scientometric Investigation and Visualization Study.
- Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis.
- SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
- Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting.
- Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.
- Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise.
- Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
- Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!
- IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
- Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
- Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials.
- Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.
- Pyoderma gangrenosum associated with dulaglutide therapy.
- The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials.
- Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
- Tirzepatide Improves Early Dumping Syndrome and Glucose Nadir in Postbariatric Hypoglycemia After Sleeve Gastrectomy.
- GLP-1 receptor agonists, CKD, and eGFR trajectory.
- Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
- Exendin-4 inhibits small intestinal glucose sensing and absorption through repression of T1R2/T1R3 sweet taste receptor signalling in streptozotocin diabetic mice.
- Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet.
- Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.
- GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.
- Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
- The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.